恩替卡韦联合前列地尔治疗乙肝肝硬化腹水的临床效果

Clinical effect of Entecavir combined with Alprostadil in the treatment of ascites caused by hepatitis B cirrhosis

目的分析乙肝肝硬化腹水患者采用恩替卡韦+前列地尔治疗的临床效果。方法选取2013年1月~2018年10月我院收治的60例乙肝肝硬化腹水患者作为研究对象,采用抽签法将其分为对照组(30例)和观察组(30例)。对照组患者采用恩替卡韦治疗,观察组患者采用恩替卡韦+前列地尔治疗。比较两组患者的治疗总有效率、不良反应总发生率、乙型肝炎病毒-脱氧核糖核酸(HBV-DNA)及肝肾功能水平,比较两组患者的随访情况。结果观察组患者的治疗总有效率(90.00%)高于对照组(60.00%),差异有统计学意义(P<0.05);观察组患者的不良反应总发生率(10.00%)低于对照组(36.67%),差异有统计学意义(P<0.05);治疗后,两组患者的清蛋白(Alb)、凝血酶原活动度(PTA)水平均高于治疗前,总胆红素(TBil)、血液尿素氮(BUN)、丙氨酸氨基转氨酶(ALT)、尿肌酐(Cr)、HBV-DNA水平均低于治疗前,差异有统计学意义(P<0.05);治疗后,观察组患者的Alb、PTA水平均高于对照组,TBil、BUN、ALT、Cr水平均低于对照组,差异有统计学意义(P<0.05)。两组患者治疗后的HBV-DNA水平比较,差异无统计学意义(P>0.05)。观察组患者的腹水增长率低于对照组,HBV-DNA阴转率高于对照组,差异有统计学意义(P<0.05)。结论医疗人员有效应用恩替卡韦+前列地尔对乙肝肝硬化腹水患者进行治疗,能够使患者的腹水症状获得显著控制,使其肝肾功能得到显著改善,促进患者的病情康复。

Objective To analyze the clinical effect of Entecavir combined with Alprostadil in the treatment of ascites caused by hepatitis B cirrhosis.Methods Sixty patients with hepatitis B cirrhosis and ascites admitted to our hospital from January 2013 to October 2018 were enrolled in the study.They were divided into control group(30 cases)and observation group(30 cases)by drawing method.Patients in the control group were treated with Entecavir,and patients in the observation group were treated with Entecavir combined with Alprostadil.The total effective rate of treatment,the total incidence of adverse reactions,hepatitis B virus-deoxyribonucleic acid(HBV-DNA)and liver and kidney function of patients in the two groups were compared,the follow-up of patients in the two groups was compared.Results The total effective rate of the observation group(90.00%)was higher than that of the control group(60.00%),the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the observation group(10.00%)was lower than that of the control group(36.67%),the difference was statistically significant(P<0.05).After treatment,the levels of albumin(Alb)and prothrombin activity(PTA)were higher than those before treatment,the total bilirubin(TBil),blood urea nitrogen(BUN),alanine aminotransferase(ALT),urinary creatinine(Cr),and HBV-DNA levels were lower than those before treatment,and the differences were statistically significant(P<0.05).After treatment,the Alb and PTA levels in the observation group were higher than those in the control group,and TBil,BUN,ALT and Cr levels in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in HBV-DNA level between the two groups after treatment(P>0.05).The ascites growth rate of the observation group was lower than that of the control group,the negative conversion rate of HBV-DNA in the group was higher than that in the control group,and the differences were statistically significant(P<0.05).Conclusion Effective application of Entecavir combined with Alprostadil in the treatment of patients with ascites caused by hepatitis B cirrhosis can significantly control the symptoms of ascites,significantly improve the liver and kidney function,and promote the rehabilitation of patients.